Observed Signal · Oct 6, 2026 · Funding · Source: a16z · Impact: 2/5 · Sentiment: Positive
a16z Leads $120M Series B in General Medicine
Andreessen Horowitz (a16z) announced it is leading a $120 million Series B funding round for General Medicine, a healthcare technology company founded by the PillPack team. General Medicine aims to create a comprehensive healthcare shopping experience by combining patient history, clinical guidance, transparent pricing, and access to care into a single platform. The company operates its own medical group alongside a marketplace of external clinicians, offering a catalog of over 2,900 health products and services. The funding will support building out the consumer offering and enterprise partnerships with health systems, payors, and pharmacies. This marks a significant investment in transforming the healthcare experience using technology.
This is a significant funding round in health technology, but not directly relevant to AdTech or MarTech industries, so importance is moderate.
Track Andreessen Horowitz (a16z) Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your free Explorer workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- a16z leads $120 million Series B in General Medicine.
- General Medicine is founded by the PillPack team, including TJ Parker, Elliot Cohen, and Ashwin Muralidharan.
- General Medicine offers a catalog of over 2,900 healthcare products and services.
- The company combines a proprietary medical group with a marketplace of external clinicians.
- Funding will support consumer offerings and enterprise partnerships with health institutions.
Connected Companies & Entities
1 Entity mapped“a16z is leading the $120M Series B in General Medicine....”
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
H1 raises $40M led by CVS Health Ventures
H1, a nine-year-old healthcare data platform, raised $40 million in a round led by CVS Health Ventures. CEO and co-founder Ariel Katz said H1 — which licenses detailed physician data to pharma companies, hospital systems and insurers — turned cash-flow and EBITDA profitable last year and is forecasting over 40% growth this year. Katz argued that being a data-first provider makes H1 less vulnerable to AI replacement and could make it a supplier to model makers. H1 was last valued at $750 million after a $100 million round in November 2021 led by Altimeter Capital, and the company has grown through acquisitions of smaller competitors and complementary businesses.
Angle Health raises $600M at $2.7B valuation
Health insurance startup Angle Health announced a $200 million Series C round and a $400 million tender offer, giving the company a $2.7 billion valuation. The round was led by Vitruvian Partners with participation from Town Hall Ventures, Blumberg Capital, Portage Ventures, PruVen Capital, and Y Combinator. The tender offer permits employees to cash out shares, and the transaction is expected to close later this month. Angle Health, a Winter 2020 Y Combinator alum, helps small businesses manage level-funded health plans, offering a middle ground between fully insured and self-funded options. The company's AI-powered platform integrates with payroll and HR systems, serves over 5,000 businesses, and is reportedly profitable. This funding round is notable as it comes from a non-AI-agent startup founded in 2019.
Tandem Health Raises $100M Series B Led by EU Fund
Stockholm-based Tandem Health, a HealthTech startup developing an AI-native operating system for European clinics, has raised $100 million (€86.49 million) in Series B funding. The round was led by EQT's Scaleup Europe Fund, marking its first healthcare investment, with participation from existing investors Kinnevik, Northzone, Amino Collective, and Visionaries. Tandem's AI co-pilot assists clinicians by generating medical notes, preparing patient summaries, aiding clinical decisions, and automating documentation; it is certified as a Class IIa medical device under EU regulations. Used by over 10,000 care organizations across 14 European markets, including the NHS, Ramsay Santé, and Humanitas, the company has now raised a total of $160 million following a $50 million Series A last year. The funding will support European expansion, growth of its clinician-led team, and the evolution into a comprehensive AI-native clinic operating system.
Track Real-Time Market Signals & Shifts
Set up custom watchlists to receive automated, evidence-grounded executive digests whenever material signals or shifts occur across your tracked landscape.